# Verdict: anti_ma2_encephalitis.md (re-re-verification pass)

## 1. DOSE LEAK
None. Grepped every numeral in the file: all are non-dose tokens (Ma2/Ma1, PNMA2, CV2/CRMP5,
"anti-CD20", "interleukin-6", "12th ed.", "Chapter 89", spelled-out "two years"). No mg, mg/m2,
AUC, g/day, or numbered cycle/day schedule anywhere — DeVita's own Ch.89 Treatment paragraph
gives exact doses (methylprednisolone 1 g/day, IVIG 0.4-2 mg/kg x5d, rituximab 375 mg/m2 weekly
x4, cyclophosphamide 1,000 mg/m2, tocilizumab 8 mg/kg monthly) and the sidecar correctly strips
all of it, naming only drug classes/agents.

## 2. UNGROUNDED / MISLABELLED CLAIMS
All four items flagged in the prior REVISE verdict are now fixed and correctly tagged, confirmed
against a fresh grep of devita.txt (no hits anywhere in the file for "orchiectomy",
"hypothalamic", "diencephalic", "narcolepsy", or "Ma1"):
1. Occult-tumor biopsy/orchiectomy claim (Tumor identification section, "If scrotal ultrasound is
   negative but suspicion remains high...") — now tagged inline "(general oncology/neurology
   standard, not from DeVita's section on this disease)". Verified DeVita Ch.89 has no
   biopsy/orchiectomy-after-negative-imaging guidance.
2. Same claim recurrence (Monitoring section, "...consideration of biopsy or orchiectomy if
   suspicion persists despite normal imaging...") — tagged with the same phrase.
3. Same claim recurrence (When to refer section, "Urgent oncologic referral for orchiectomy or
   biopsy...despite normal imaging") — tagged with the same phrase.
4. Minor/secondary gap ("the choice among them is generally guided by severity and local
   practice rather than antibody type") — now tagged "(general standard, not from DeVita's
   section on this disease)".

Everything else re-checked clean and grounded against DeVita Ch.89 text directly: Table 89.1
framing (Ma2 -> high-risk antibody, LE/brainstem encephalitis phenotype with oculomotor
symptoms/dysarthria/dysphagia, testicular cancer + NSCLC association, "anti-Ma2 with testicular
seminoma"), "treat primary tumor in addition to immunotherapy" (matches DeVita's own wording),
repeat-screening-for-~2-years window, first-line list (steroids/IVIG/plasma exchange, doses
stripped), second-line list (rituximab, azathioprine, MMF, cyclophosphamide — drug names only,
matches DeVita), tocilizumab-effective-post-rituximab-failure claim (matches DeVita verbatim
sense), the surface-vs-intracellular-antigen response-rate statement (matches DeVita: "PNS
associated with antibodies to surface antigens respond better... than those with antibodies
against intracellular antigens"), and the Ma1/Ma2 age-tumor split plus Ma2-as-intracellular-
antigen classification, both still correctly tagged as general literature/not-from-DeVita
(re-confirmed: "Ma1" does not appear anywhere in devita.txt, and DeVita's excerpt never assigns
Ma2 specifically to the intracellular-antigen category).

No claim remains mis-attributed to DeVita, and no previously-tagged item was left untouched by
mistake.

## 3. CITATION
Present, name-only, no page numbers: "DeVita, Hellman, and Rosenberg's Cancer: Principles &
Practice of Oncology, 12th ed. (Chapter 89, Paraneoplastic Syndromes)." Correct.

No em/en dashes found anywhere in the file (confirmed by grep).

## 4. VERDICT: CLEAN
Ready for R1 re-review. All four previously-flagged gaps are now correctly tagged, no dose
leak, no mis-attribution to DeVita, citation format is compliant.
